Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE
American: DSS), a multinational company operating business segments
in blockchain security, direct marketing, healthcare, consumer
packaging, real estate, renewable energy, and securitized digital
assets, announced today that its subsidiary, DSS Biomedical
International, Inc. (“DSS Biomedical”), completed a $1 million
equity investment in Vivacitas Oncology, Inc. (“Vivacitas”), a
clinical-stage company focused on difficult-to-treat cancers.
“We continue to demonstrate our commitment to
addressing unmet needs in human healthcare and wellness through key
strategic investments,” stated Frank D. Heuszel, CEO of DSS. “With
a rich pipeline of promising assets, Vivacitas provides significant
upside potential.”
Vivacitas Oncology Inc. focuses on developing
new treatment options to treat cancers resistant to currently
available therapies. It originated in 2015 with the vision of Dr.
Joseph Rubinfeld (co-founder of Amgen) and the endorsement of
Infusion 51a, LP (infusion51a.com), an impact investment fund
designed to create value in underappreciated companies from the
Precision Medicine and BioTech industry.
Vivacitas’ lead development candidate (AR-67) is
a novel lipophilic next-generation camptothecin (Topiosomerase-1
enzyme inhibitor) compound with the potential to deliver improved
efficacy and tolerability, employing a proprietary synthesis
method.
AR-67 has in vitro, Phase I, and Phase II data
in multiple solid tumor types. For instance, it has demonstrated
potential improvement in progression-free survival (6-29 months) in
glioblastoma patients, while significantly reducing severe side
effects usually associated with this drug class (e.g., grade 4
diarrhea).
Jeffrey Stephens, founder, CEO and director of
Infusion 51a and board member of Vivacitas Oncology said,
“Vivacitas Oncology is excited to work with DSS and the Impact
BioMedical team as we continue to execute on our efforts to expand
Vivacitas operations and develop new treatment options for cancer
patients worldwide.”
About Impact BioMedical,
Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is
a wholly owned subsidiary of DSS and a unique technology source,
developer, and business partner in addressing unmet needs in human
healthcare and wellness. For more information on Impact BioMedical
visit http://impbio.com/.
About Document Security Systems,
Inc.
DSS is a multinational company operating
business segments in blockchain security, direct marketing,
healthcare, consumer packaging, real estate, renewable energy, and
securitized digital assets. Its business model is based on a
distribution sharing system in which shareholders will receive
shares in its subsidiaries as DSS strategically spins them out into
IPOs. Its historic business revolves around counterfeit deterrent
and authentication technologies, smart packaging, and consumer
product engagement. DSS is led by its Chairman, Mr. Fai Chan, a
highly successful global business veteran of more than 40 years
specializing in corporate transformation while managing risk. He
has successfully restructured more than 35 corporations with a
combined value of $25 billion.
For more information on DSS
visit http://www.dsssecure.com.Investor Contact:Dave Gentry,
CEORedChip Companies Inc.407-491-4498Dave@redchip.com
About Vivacitas Oncology,
Inc.
Vivacitas Oncology is a private clinical stage
biopharmaceutical company focused on combating those cancers that
have proven to be frustratingly resistant to current treatment
modalities. It originated with the vision of Dr. Joseph Rubinfeld
(co-founder of Amgen) and Infusion 51a, LP with the intent to
improve upon well-known chemotherapies with demonstrated effect,
but which also possess challenges with potency, toxicity,
stability, and other issues limiting their use. Through an enduring
spirit, Vivacitas continues to apply clarity, tenacity, and vision
in our fight against intractable cancers and our pursuit of new
treatment options for patients and their families worldwide.
For further information please
visit www.vivaoncology.com or Elise@vivaoncology.com.
Safe Harbor Disclosure
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements include, but are not
limited to, statements related to the Company's intended use of
proceeds and other statements that are not historical facts.
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that may
cause actual results or events to differ materially from those
projected. These risks and uncertainties, many of which are beyond
our control, include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of development activities; our ability to attract,
integrate and retain key personnel; our need for substantial
additional funds; patent and intellectual property matters;
competition; as well as other risks described in the section
entitled "Risk Factors" in the prospectus and in our other filings
with the SEC, including, without limitation, our reports on Forms
8-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024